Portfolio overview

Oblique Therapeutics currently has five development programs in its pipeline: four are FTABS™ antibodies obtained with Abiprot™ within pain, advanced cancer and diabetes with a fifth program being a small molecule anticancer agent. Of these, two programs are developed in collaboration with leading pharmaceutical companies in their respective fields.